GHDX - ゲノミック・ヘルス (Genomic Health Inc.) ゲノミック・ヘルス

 GHDXのチャート


 GHDXの企業情報

symbol GHDx
会社名 Genomic Health Inc (ゲノミック・ヘルス)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical Specialities  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ジェノミック・ヘルス(Genomic Health Inc.)はがん治療をパーソナライズするためのゲノムベースの診断テストを提供するヘルスケア会社である。同社は、ゲノムベースの臨床検査サービスを開発・商品化している。同社のオンコタイプIQゲノムインテリジェンスプラットフォームは、Oncotype DX遺伝子発現試験の主要なラインとそのOncotype SEQ液体選択テストで構成される。同社の研究開発活動は、乳癌、結腸癌、前立腺癌および他の癌を含む各種の癌の治療を最適化するための検査のパイプライン開発に焦点を当てている。同社は腫瘍組織サンプル中の遺伝子の発現レベルを分析し、医師に単一定量的スコアとして表される定量的遺伝子発現プロファイルを提供する臨床検査サービスとしてOncotype DX検査を提供し、浸潤性乳癌の再発スコア(DCIS)、および前立腺癌治療用のゲノム前立腺スコアが含まれるが、これらに限定されない。   ゲノミック・ヘルスは米国でがんの個別化治療のためのゲノム解析(遺伝子検査)を行う。侵潤性乳がん、結腸がん、前立腺がん用の腫瘍の大きさ、悪性度、再発性、化学療法の効果性などの情報を提供するオンコタイプDX検査を行う。また、他のがんに対するオンコタイプDX検査の臨床研究を行う。   Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. Genomic Health was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott, and Steven Shak in August 2000 and is headquartered in Redwood City, CA.
本社所在地 301 Penobscot Drive Redwood City CA 94063 USA
代表者氏名 Kimberly J. Popovits Kimberly J. Popovits
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 650-556-9300
設立年月日 36739
市場名 NASDAQ National Market System
ipoyear 2005年
従業員数 863人
url www.genomichealth.com
nasdaq_url https://www.nasdaq.com/symbol/ghdx
adr_tso
EBITDA EBITDA(百万ドル) 14.77900
終値(lastsale) 64.82
時価総額(marketcap) 2324136203.06
時価総額 時価総額(百万ドル) 2309.077
売上高 売上高(百万ドル) 359.52800
企業価値(EV) 企業価値(EV)(百万ドル) 2156.132
当期純利益 当期純利益(百万ドル) 4.23000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Genomic Health Inc. revenues increased 11% to $188.2M. Net income totaled $4.5M vs. loss of $3.5M. Revenues reflect United States segment increase of 12% to $160.3M. Net Income reflects Promotional and marketing materials decrease of 27% to $5.9M (expense) Bad Debts expense decrease from $1.6M (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.10 to $0.13.

 GHDXのテクニカル分析


 GHDXのニュース

   Why the Earnings Surprise Streak Could Continue for Genomic Health (GHDX)  2019/11/08 15:10:03 Zacks Investment Research
Genomic Health (GHDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
   Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company  2019/11/08 13:03:00 PR Newswire
Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth MADISON, Wis., Nov. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced…
   Genomic Health, Inc. (GHDX): Hedge Funds Cashed Out Too Early  2019/10/27 02:20:56 ACI Information Group
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make
   Innovation Aids Genomic Health, Merger Procedure on Track  2019/09/04 15:27:00 Zacks Investment Research
Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.
   Genomic Health, Inc. (GHDX) Shares March Higher, Can It Continue?  2019/08/05 14:35:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Genomic Health, Inc. (GHDX).
   Why the Earnings Surprise Streak Could Continue for Genomic Health (GHDX)  2019/11/08 15:10:03 Zacks Investment Research
Genomic Health (GHDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
   Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company  2019/11/08 13:03:00 PR Newswire
Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth MADISON, Wis., Nov. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced…
   Genomic Health, Inc. (GHDX): Hedge Funds Cashed Out Too Early  2019/10/27 02:20:56 ACI Information Group
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make
   Innovation Aids Genomic Health, Merger Procedure on Track  2019/09/04 15:27:00 Zacks Investment Research
Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.
   Genomic Health, Inc. (GHDX) Shares March Higher, Can It Continue?  2019/08/05 14:35:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Genomic Health, Inc. (GHDX).
   Bulletproof Investing Performance Update: Week 71  2019-04-05
Safety First: NASCAR driver Johanna Long and her helmet (Credit: Gearheads ) Bulletproof Investing: Week 71 Performance Each week since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers….

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ゲノミック・ヘルス GHDX Genomic Health Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)